IKZF1 and acute myeloid leukemia: For AML, we demonstrate that somatically acquired IKZF1N159S mutations are an independent prognostic marker for poor clinical outcome, associated with a specific co‐mutational profile, which is also different from AML patients with other IKZF1 mutations.6, 7